Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | EGFR | P00533 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.49 |
| ▸ | CAMK2A | Q9UQM7 | 5/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30581858 | 1.00 | ALDH1A1 (0.51) | ALDH1A1EGFRKDM4EGAAGLA | |
| SCHEMBL2978593 | 0.86 | EGFR (0.55) | ALDH1A1EGFRKDM4EGAAGLA | |
| SCHEMBL837451 | 0.84 | ALDH1A1 (0.56) | ALDH1A1KDM4EGAAHTTMEN1 | |
| SCHEMBL8138023 | 0.84 | EGFR (0.59) | ALDH1A1EGFRKDM4EGAAGLA | |
| SCHEMBL1744734 | 0.83 | KDM4E (0.43) | ALDH1A1KDM4EGAAGLAL3MBTL1 | |
| SCHEMBL1525623 | 0.83 | ALDH1A1 (0.54) | ALDH1A1KDM4EGAAHTTMEN1 | |
| SCHEMBL9610136 | 0.83 | ALDH1A1 (0.42) | ALDH1A1KDM4EGLAHSP90AB1HTT | |
| SCHEMBL30619656 | 0.82 | EGFR (0.57) | ALDH1A1EGFRKDM4EGAAGLA | |
| SCHEMBL8764395 | 0.82 | EGFR (0.57) | ALDH1A1EGFRKDM4EGAAGLA | |
| SCHEMBL1627073 | 0.81 | EPHX2 (0.48) | ALDH1A1KDM4EGAAHSP90AB1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023161317-A1 | 5-[7-(3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBONYL)-1,2,3,4 TETRAHYDROISOQUINOLIN-6-Y L]-1H-PYRROLE-3-CARBOXAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS | LES LABORATOIRES SERVIER (FR) | 2023-08-31 | — | — | WO | disclosed |
| EP-1660504-B1 | THIENOPYRIDINE-PHENYLACET AMIDES AND THEIR DERIVATIVES USEFUL AS NEW ANTI-ANGIOGENIC AGENTS | PFIZER (US) | 2008-10-29 | — | — | EP | disclosed |
| EP-1660504-B1 | THIENOPYRIDINE-PHENYLACET AMIDES AND THEIR DERIVATIVES USEFUL AS NEW ANTI-ANGIOGENIC AGENTS | PFIZER (US) | 2008-10-29 | — | — | EP | disclosed |
| US-7208500-B2 | Thienopyridine-phenylacetamides and their derivatives useful as new anti-angiogenic agents | AGOURON PHARMACEUTICALS, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208500-B2 | Thienopyridine-phenylacetamides and their derivatives useful as new anti-angiogenic agents | AGOURON PHARMACEUTICALS, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208500-B2 | Thienopyridine-phenylacetamides and their derivatives useful as new anti-angiogenic agents | AGOURON PHARMACEUTICALS, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| EP-1660504-A1 | THIENOPYRIDINE-PHENYLACET AMIDES AND THEIR DERIVATIVES USEFUL AS NEW ANTI-ANGIOGENIC AGENTS | PFIZER INC. (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20050090509-A1 | Thienopyridine-phenylacetamides and their derivatives useful as new anti-angiogenic agents | Agouron Pharmaceuticals,Inc. | 2005-04-28 | — | — | US | disclosed |
| WO-2005021554-A1 | THIENOPYRIDINE-PHENYLACET AMIDES AND THEIR DERIVATIVES USEFUL AS NEW ANTI-ANGIOGENIC AGENTS | PFIZER INC. (US) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090509-A1 | Thienopyridine-phenylacetamides and their derivatives useful as new anti-angiogenic agents | CCNA1, PGF, CCNA2 | ALDH1A1 537/4885EGFR 694/4885KDM4E 1525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.